Nature Communications (Jan 2024)

Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity

  • Xue Zhang,
  • Shishir M. Pant,
  • Cecily C. Ritch,
  • Hsin-Yao Tang,
  • Hongguang Shao,
  • Harsh Dweep,
  • Yao-Yu Gong,
  • Rebekah Brooks,
  • Patricia Brafford,
  • Adam J. Wolpaw,
  • Yool Lee,
  • Ashani Weeraratna,
  • Amita Sehgal,
  • Meenhard Herlyn,
  • Andrew Kossenkov,
  • David Speicher,
  • Peter K. Sorger,
  • Sandro Santagata,
  • Chi V. Dang

DOI
https://doi.org/10.1038/s41467-024-44778-2
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma tumor growth. Loss of Bmal1 in YUMM2.1 or B16-F10 melanoma cells eliminates clock function and diminishes hypoxic gene expression and tumorigenesis, which could be rescued by ectopic expression of HIF1α in YUMM2.1 cells. By contrast, over-expressed wild-type or a transcriptionally inactive mutant Bmal1 non-canonically sequester myosin heavy chain 9 (Myh9) to increase MRTF-SRF activity and AP-1 transcriptional signature, and shift YUMM2.1 cells from a Sox10high to a Sox9high immune resistant, mesenchymal cell state that is found in human melanomas. Our work describes a link between Bmal1, Myh9, mouse melanoma cell plasticity, and tumor immunity. This connection may underlie cancer therapeutic resistance and underpin the link between the circadian clock, MRTF-SRF and the cytoskeleton.